Sodhi Rajwant
Known title: DirectorCIK: 0001715325
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
ResMed Q4 2026 Earnings Call Transcript Released. ResMed has released the transcript for its Q4 2026 earnings call, providing investors with detailed insights into the company's recent performance. This follows a quarterly earnings preview and places the stock within a broader market forecast for the mHealth sector. The release offers a factual record of management's comments on financial results and strategic direction.
Transaction History
| TNDM | ▲ Buy | Option Exercise | 8,759 | $0 | 5/21/2026 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 4,387 | $91K | 5/22/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 4,434 | $229K | 5/24/2024 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 1,070 | $30K | 1/4/2024 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 2,757 | $0 | 5/25/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 1,069 | $0 | 1/4/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 735 | $0 | 5/18/2022 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 1,069 | $0 | 1/4/2022 | View on chart |
| RMD | ▼ Sell | Open Market | 1,500 | $433K | 9/1/2021 | View on chart |
| RMD | ▲ Buy | Grant | 4,066 | $0 | 8/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating
Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating. Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.